克拉斯
PI3K/AKT/mTOR通路
效应器
癌症研究
MAPK/ERK通路
清脆的
信号转导
后天抵抗
化学
抗凋亡Ras信号级联
胰腺癌
生物
细胞生物学
癌症
细胞信号
下调和上调
功能(生物学)
突变
作者
Xiangyu Ge,Jaffarguriqbal Singh,Wenxue Li,Cassandra S. Markham,Christian Felipe Ruiz,Edward C. Stites,Moitrayee Bhattacharyya,Yansheng Liu,Mandar Deepak Muzumdar
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2026-05-06
卷期号:86 (15): 3819-3837
被引量:1
标识
DOI:10.1158/0008-5472.can-25-3625
摘要
Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle. We showed here that phosphoinositide 3-kinase (PI3K) plays a major role in this resistance through upstream activation of wild-type (WT) RAS signaling-beyond its known KRAS effector function. The combination of proximity labeling, CRISPR screening, live-cell imaging, and functional assays revealed that PI3K orchestrates phosphoinositide-mediated GAB1 recruitment to the plasma membrane, nucleating assembly of RAS signaling complexes that activate mitogen-activated protein kinase (MAPK) in an EGFR/SHP2/SOS1-dependent manner. Inhibiting PI3K enhanced sensitivity to mutant-specific KRAS inhibitors in PDAC cells, including in cells with clinically identified PIK3CA mutations. These findings refine RAS-PI3K signaling paradigms, reveal that PI3K-driven WT RAS activation drives resistance to KRAS inhibition, and illuminate avenues for augmenting KRAS-targeted therapies in PDAC. SIGNIFICANCE: PI3K plays a functional upstream role in assembling wild-type RAS signaling complexes that confer KRAS inhibitor resistance, providing a rationale for combined targeting of PI3K and KRAS in pancreatic cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI